Grapefruit Products Interactions

Grapefruit products should be avoided due to CYP3A4 inhibition, which increases abemaciclib exposure and toxicity risk.

Source: NLP:abemaciclib

May increase axitinib plasma concentrations and should be avoided.

Source: NLP:axitinib

Strong CYP3A4 inhibitor increases erlotinib exposure, raising risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable.

Source: NLP:erlotinib

CYP3A inhibitor that may increase nifedipine exposure. Careful monitoring and dose adjustment necessary; consider lowest dose.

Source: NLP:nifedipine

Strong CYP3A inhibitor. Increases nirogacestat exposure, which may increase risk of adverse reactions.

Source: NLP:nirogacestat

Grapefruit may increase exposure of cabozantinib, increasing risk of exposure-related adverse reactions. Avoid coadministration or reduce CABOMETYX dosage.

Source: NLP:cabozantinib

Grapefruit products contain CYP3A inhibitors that increase entrectinib concentrations. Avoid grapefruit products during treatment.

Source: NLP:entrectinib

Contains strong or moderate CYP3A inhibitors. Should be avoided during ibrutinib treatment to prevent increased ibrutinib concentrations.

Source: NLP:ibrutinib

Grapefruit is a moderate CYP3A inhibitor. Concomitant use increases rilzabrutinib exposure and risk of adverse reactions.

Source: NLP:rilzabrutinib